CVRx (CVRX) Stock Forecast & Price Target

CVRx Inc. has demonstrated strong growth potential, highlighted by an increase in active implanting centers, which rose to 240 by the end of the quarter, marking a sequential gain of 13 centers. Despite an approximately 8% year-over-year increase in total operating expenses, which reached $25.8 million largely due to a significant rise in selling, general, and administrative expenses, the company's strategic positioning in the neuromodulation space remains robust. The focus on its proprietary Barostim technology, aimed at addressing cardiovascular diseases, positions CVRx favorably within a growing market, particularly given that the majority of its revenue is derived from the U.S. market.

CVRx reported a reduced revenue guidance for FY25, adjusting the top end to a range of $55.0 - $57.0 million, which indicates a modest growth rate of approximately 7-11% year-over-year, reflecting a slowdown compared to previous expectations. Furthermore, the company has also revised its revenue estimate for 2026 down to $67.6 million from $74.1 million, signifying a moderated growth trajectory in the U.S. market. Additionally, despite maintaining a gross margin of around 84% in Q2 2025, the overall outlook remains concerning due to lowered expectations and stagnation in revenue growth.